Nano-carriers

纳米载体
  • 文章类型: Journal Article
    再生医学中采用了许多用于再生受损组织或退化细胞的策略。干细胞技术是最近方法的现代策略,特别是使用间充质干细胞(MCSs)。MSC的分化能力以及它们作为旁分泌效应物的特征性行为已将它们确立为组织修复中的关键要素(Shaer等人。,20141).最近,由MSCs脱落的细胞外囊泡(EV)已成为一种有前途的无细胞疗法(引用}Rani,S、Ryan,A.E.,格里芬,M.D.,还有Ritter,T.,20152).这篇全面的综述涵盖了MSC衍生的外泌体及其作为纳米治疗剂的治疗潜力。我们还讨论了它们与脂质体相比作为药物递送纳米载体的效力。更好地了解电动汽车在体内的行为及其作用机制是确定试点研究中最佳配方参数和建立工业过程的关键。
    Many strategies for regenerating the damaged tissues or degenerating cells are employed in regenerative medicine. Stem cell technology is a modern strategy of the recent approaches, particularly the use of mesenchymal stem cells (MCSs). The ability of MSCs to differentiate as well as their characteristic behaviour as paracrine effector has established them as key elements in tissue repair (Shaer et al., 20141). Recently, extracellular vesicles (EVs) shed by MSCs have emerged as a promising cell free therapy (Citation}Rani, S., Ryan, A. E., Griffin, M. D., and Ritter, T., 20152). This comprehensive review encompasses MSCs-derived exosomes and their therapeutic potential as nanotherapeutics. We also discuss their potency as drug delivery nano-carriers in comparison with liposomes. A better knowledge of EVs behaviour in vivo and of their mechanism of action are key to determine parameters of an optimal formulation in pilot studies and to establish industrial processes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    糖尿病是一种慢性代谢性疾病,其特征是血糖水平升高,包括各种类型,如1型,2型,妊娠,和糖尿病前期。这篇综述探讨了2型糖尿病的复杂性及其理想管理。目前,一系列草药和合成药物用于2型糖尿病的管理。我们从截至2024年发表的文章中收集了有关糖尿病的信息,并在PubMed中列出,WebofScience,Elsevier,谷歌学者,类似的数据库。我们搜索的关键词包括"糖尿病",“草药”,\"纳米载体\",“透皮给药”,等。通过仔细分析2型糖尿病的研究,人们发现,以糖尿病为基础的研究有所增加,这可以通过考虑PubMed搜索引擎结果来证明,该结果使用2型糖尿病的透皮给药作为关键字。这些药物的口服消耗与许多副作用有关,包括肥胖,胰腺癌,荷尔蒙失衡。为了克服这些挑战,纳米载体和透皮给药系统的利用成为提高药物疗效的有希望的途径。纳米载体代表了一种革命性的方法,整合尖端技术,创造性的策略,以及以安全有效的浓度递送活性分子的方法,从而引发所需的药理学反应。这篇综述严格审查了与传统口服抗糖尿病药物相关的限制,并强调了为彻底改变药物输送而采取的多种举措。这篇综述的重点是与常规口服抗糖尿病药物相关的局限性,以及迄今为止使用创新成分和技术有效和安全地输送药物的许多举措。
    Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels and encompasses various types like type 1, type 2, gestational, and prediabetes. This review delves into the intricacies of type-2 diabetes mellitus and its ideal management. Presently, a spectrum of herbal and synthetic drugs is employed for type-2 diabetes mellitus management. We gathered information about diabetes mellitus from articles published up to 2024 and listed in PubMed, Web of Science, Elsevier, Google Scholar, and similar databases. The keywords used in our search included \"diabetes\", \"herbal drugs\", \"nano-carriers\", \"transdermal drug delivery\", etc. By carefully analyzing the research on type-2 diabetes-mellitus, it was found that there is an increase in diabetes-based research, which can be demonstrated by contemplating the PubMed search engine results using transdermal delivery for type-2 diabetes-mellitus as a keyword. The oral consumption of these drugs is associated with numerous side effects, including obesity, pancreatic cancer, and hormonal imbalances. To surmount these challenges, the utilization of nano-carriers and transdermal drug delivery systems emerges as a promising avenue aiming to enhance the therapeutic efficacy of drugs. Nano-carriers represent a revolutionary approach, integrating cutting-edge technologies, inventive strategies, and methodologies to deliver active molecules in concentrations that are both safe and effective, thereby eliciting the desired pharmacological response. This review critically examines the constraints associated with traditional oral administration of anti-diabetic drugs and underscores the manifold initiatives undertaken to revolutionize drug delivery. This review focuses on the limitations associated with the conventional oral administration of anti-diabetic drugs and the many initiatives made so far for the effective and safe delivery of drugs using innovative constituents and techniques.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    海洋产品由于其宝贵的成分而受到欢迎,尤其是蛋白质,尽管产生了巨大的浪费。蛋白质水解产物被广泛认为是将这些低价值原料转化为高价值产品的最有效方法。鱼蛋白水解物(FPH),来自各种水生废物,如骨头,scales,皮肤,和其他人,富含蛋白质的高附加值产品。然而,疏水性肽具有局限性,如令人不快的味道和高溶解度。微囊化技术提供了解决这些限制和保护生物活性肽的科学方法。本文综述了FPH生产方法及其抗氧化和抗菌活性的最新研究。使用商业酶的酶水解被确定为最佳方法,并证实了FPH的抗氧化和抗菌性能。使用纳米脂质体的微囊化有效地扩展了抑制活性并增强了抗氧化和抗菌能力。然而,需要更多的研究来减轻与FPH相关的苦味并增强感官属性。
    Marine products have gained popularity due to their valuable components, especially protein, despite generating significant waste. Protein hydrolysates are widely recognized as the most effective method for transforming these low-value raw materials into high-value products. Fish protein hydrolysate (FPH), sourced from various aquatic wastes such as bones, scales, skin, and others, is rich in protein for value-added products. However, the hydrophobic peptides have limitations like an unpleasant taste and high solubility. Microencapsulation techniques provide a scientific approach to address these limitations and safeguard bioactive peptides. This review examines current research on FPH production methods and their antioxidant and antibacterial activities. Enzymatic hydrolysis using commercial enzymes is identified as the optimal method, and the antioxidant and antibacterial properties of FPH are substantiated. Microencapsulation using nanoliposomes effectively extends the inhibitory activity and enhances antioxidant and antibacterial capacities. Nevertheless, more research is needed to mitigate the bitter taste associated with FPH and enhance sensory attributes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    基于纳米颗粒的递送系统已经成为害虫管理领域的强大工具,提供精确有效的双链RNA(dsRNA)传递方式,通过RNA干扰(RNAi)控制害虫的有效试剂。这篇综合综述旨在评估和比较各种类型的纳米颗粒在dsRNA递送中的适用性,以用于害虫管理应用。该综述首先考察了不同纳米颗粒材料的独特性能和优势,包括粘土,壳聚糖,脂质体,碳,金和二氧化硅。评估每种材料保护dsRNA免于降解的能力及其靶向递送至害虫的潜力。此外,这篇综述深入研究了用于增强dsRNA递送效率的表面修饰策略。用寡核苷酸功能化,脂质,聚合物,详细讨论了蛋白质和肽,强调它们在提高稳定性方面的作用,细胞摄取,和dsRNA递送的特异性。这篇综述还为选择最合适的基于纳米颗粒的系统在害虫管理中有效和可持续地递送dsRNA提供了有价值的指导。此外,它确定了现有的知识差距,并提出了潜在的研究方向,旨在通过利用纳米颗粒和dsRNA来加强害虫控制策略。
    Nanoparticle-based delivery systems have emerged as powerful tools in the field of pest management, offering precise and effective means of delivering double-stranded RNA (dsRNA), a potent agent for pest control through RNA interference (RNAi). This comprehensive review aims to evaluate and compare various types of nanoparticles for their suitability in dsRNA delivery for pest management applications. The review begins by examining the unique properties and advantages of different nanoparticle materials, including clay, chitosan, liposomes, carbon, gold and silica. Each material\'s ability to protect dsRNA from degradation and its potential for targeted delivery to pests are assessed. Furthermore, this review delves into the surface modification strategies employed to enhance dsRNA delivery efficiency. Functionalization with oligonucleotides, lipids, polymers, proteins and peptides is discussed in detail, highlighting their role in improving stability, cellular uptake, and specificity of dsRNA delivery.This review also provides valuable guidance on choosing the most suitable nanoparticle-based system for delivering dsRNA effectively and sustainably in pest management. Moreover, it identifies existing knowledge gaps and proposes potential research directions aimed at enhancing pest control strategies through the utilization of nanoparticles and dsRNA.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    细菌感染和抗生素耐药性的持续增加是寻找具有新型作用方式的新型抗菌剂的驱动力。抗菌肽(AMP)作为具有治疗耐药性感染潜力的有前途的抗生素剂,最近受到关注。与常规抗生素相比,几种AMP显示出较低的耐药性倾向。然而,这些肽,尤其是存在不利药代动力学特性的酰基缩肽(ADEP),如高毒性和低生物利用度。已经探索了将这些肽改善为药物样分子的不同方法,这些包括使用生物相容性纳米载体。ADEP1类似物(SC005-8)与明胶封端的银/铟/硫化物(AgInS2)量子点(QDs)缀合,提高了对革兰氏阴性(大肠杆菌和铜绿假单胞菌)的抗菌活性,和革兰氏阳性(枯草芽孢杆菌,金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌)细菌。ADEP1类似物的最小抑制浓度(MIC)在63至500µM之间,和最小杀菌浓度(MBC)值在125和750µM之间。AgInS2-ADEP1类似物缀合物显示出增强的抗菌活性,如MIC和MBC值所示,即,1.6-25µM和6.3-100µM,分别。AgInS2-ADEP1类似物缀合物在显示抗菌活性的浓度下对HEK-293细胞无毒。本文报道的发现可能有助于开发抗菌治疗策略。
    The continuous rise in bacterial infections and antibiotic resistance is the driving force behind the search for new antibacterial agents with novel modes of action. Antimicrobial peptides (AMPs) have recently gained attention as promising antibiotic agents with the potential to treat drug-resistant infections. Several AMPs have shown a lower propensity towards developing resistance compared to conventional antibiotics. However, these peptides, especially acyldepsipeptides (ADEPs) present with unfavorable pharmacokinetic properties, such as high toxicity and low bioavailability. Different ways to improve these peptides to be drug-like molecules have been explored, and these include using biocompatible nano-carriers. ADEP1 analogues (SC005-8) conjugated to gelatin-capped Silver/Indium/Sulfide (AgInS2) quantum dots (QDs) improved the antibacterial activity against Gram-negative (Escherichia coli and Pseudomonas aeruginosa), and Gram-positive (Bacillus subtilis, Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus) bacteria. The ADEP1 analogues exhibited minimum inhibition concentrations (MIC) between 63 and 500 µM, and minimum bactericidal concentrations (MBC) values between 125 and 750 µM. The AgInS2-ADEP1 analogue conjugates showed enhanced antibacterial activity as evident from the MIC and MBC values, i.e., 1.6-25 µM and 6.3-100 µM, respectively. The AgInS2-ADEP1 analogue conjugates were non-toxic against HEK-293 cells at concentrations that showed antibacterial activity. The findings reported herein could be helpful in the development of antibacterial treatment strategies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    寄生虫引起的疾病具有从轻度到重度的广泛症状,并对世界上大量的疫情负责。当前的抗寄生虫药物是有毒的并且具有显著的副作用。纳米载体被认为通过减少副作用和增加靶递送和药物渗透性以及药物的受控延长释放来消除常规药物的限制。固体脂质纳米颗粒(SLN)是脂质纳米颗粒(LNP),这是经常练习的。合适的释放速率,稳定性,和目标递送使SLN成为胶体载体的良好替代品。SLN被认为具有提供具有抗寄生虫特性的天然产物的巨大潜力。纳米粒子已用于提高SLN的稳定性和容量负载,近年来。这篇综述描述了SLN的发展,制备方法,表征,并在寄生虫病中将药物装载到SLN中。此外,我们总结了抗寄生虫SLN负载药物的最新进展。
    Parasites cause illnesses with broad spectrum of symptoms from mild to severe, and are responsible for a significant number of outbreaks in the world. Current anti-parasitic drugs are toxic and have significant side effects. Nano-carriers are believed to obviate the limitations of conventional drugs via decreasing side effects and increasing target delivery and drug permeability with a controlled prolonged release of a drug. Solid lipid nanoparticles (SLNs) are lipid nanoparticles (LNPs), which have frequently been practiced. Suitable release rate, stability, and target delivery make SLNs a good alternative for colloidal carriers. SLNs are supposed to have great potential to deliver natural products with anti-parasitic properties. Nanoparticles have employed to improve stability and capacity loading of SLNs, during recent years. This review describes development of SLNs, the methods of preparation, characterization, and loaded drugs into SLNs in parasitic diseases. In addition, we summarize recent development in anti-parasitic SLNs-loaded drugs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    结核病(TB)是一个主要的全球健康问题,也是仅次于COVID-19的第二大流行传染性杀手。它是由结核分枝杆菌(Mtb)引起的,并且由于耐药性而变得越来越具有挑战性。世界卫生组织于1993年宣布结核病为全球卫生紧急情况。结核病的耐药性是由细菌基因组中的突变驱动的,这些突变可能受到长时间药物暴露和患者依从性差的影响。耐药结核病的发展,例如多药耐药,广泛耐药,完全耐药,带来了重大的治疗挑战。研究人员正在探索新药和新型药物递送系统,例如基于纳米技术的疗法,对抗抗药性。纳米药物递送提供有针对性和精确的药物递送,提高治疗效果,减少不良影响。随着纳米药物输送,具有强大治疗功效的新一代抗生素,药物再利用,和新的治疗方案(组合),可以在较短的持续时间内解决耐药性的问题,可能是有希望的治疗方法在临床设置。然而,纳米药物的临床翻译面临着安全性等挑战,大规模生产,监管框架,和知识产权问题。在这次审查中,我们现在的状态,最新发现,挑战,以及限制使用乳剂和纳米颗粒对抗耐药结核病的障碍。
    Tuberculosis (TB) is a major global health problem and the second most prevalent infectious killer after COVID-19. It is caused by Mycobacterium tuberculosis (Mtb) and has become increasingly challenging to treat due to drug resistance. The World Health Organization declared TB a global health emergency in 1993. Drug resistance in TB is driven by mutations in the bacterial genome that can be influenced by prolonged drug exposure and poor patient adherence. The development of drug-resistant forms of TB, such as multidrug resistant, extensively drug resistant, and totally drug resistant, poses significant therapeutic challenges. Researchers are exploring new drugs and novel drug delivery systems, such as nanotechnology-based therapies, to combat drug resistance. Nanodrug delivery offers targeted and precise drug delivery, improves treatment efficacy, and reduces adverse effects. Along with nanoscale drug delivery, a new generation of antibiotics with potent therapeutic efficacy, drug repurposing, and new treatment regimens (combinations) that can tackle the problem of drug resistance in a shorter duration could be promising therapies in clinical settings. However, the clinical translation of nanomedicines faces challenges such as safety, large-scale production, regulatory frameworks, and intellectual property issues. In this review, we present the current status, most recent findings, challenges, and limiting barriers to the use of emulsions and nanoparticles against drug-resistant TB.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    DNA逻辑电路(DLC)可以准确识别特定的细胞类型,比如癌细胞,但他们面临的挑战是微弱的输出信号和缺乏能够有效地将DLC组件输送到活体中的目标部位的有能力的平台。为了解决这些问题,我们合理地介绍了一种基于引物交换反应的级联生物放大器模块,该模块受电子电路放大器器件的启发。作为一种范式,三种异常表达的Hela细胞microRNAs(-30a,-17和-21)被选为“与”门输入。对这些输入的DLC响应通过放大器显著增强输出信号而增强。更重要的是,将DLC和放大器组分封装到ZIF-8纳米粒子中导致它们有效地递送到靶位点,在体内成功区分Hela肿瘤亚型与其他肿瘤。因此,我们设想这一策略在临床癌症诊断中具有巨大潜力.
    DNA logic circuits (DLC) enable the accurate identification of specific cell types, such as cancer cells, but they face the challenges of weak output signals and a lack of competent platforms that can efficiently deliver DLC components to the target site in the living body. To address these issues, we rationally introduced a cascaded biological amplifier module based on the Primer Exchange Reaction inspired by electronic circuit amplifier devices. As a paradigm, three abnormally expressed Hela cell microRNAs (-30a, -17, and -21) were chosen as \"AND\" gate inputs. DLC response to these inputs was boosted by the amplifier markedly enhancing the output signal. More importantly, the encapsulation of DLC and amplifier components into ZIF-8 nanoparticles resulted in their efficient delivery to the target site, successfully distinguishing the Hela tumor subtype from other tumors in vivo. Thus, we envision that this strategy has great potential for clinical cancer diagnosis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    伤口的治疗在全世界都是一个严重的问题,给每个国家带来了巨大的财政负担。很长一段时间,研究人员已经探索了加速伤口愈合的伤口敷料。传统的伤口敷料不能如预期的那样有效地响应伤口愈合过程。自古以来,源自植物提取物和提取的生物活性成分的治疗活性物质已在全球各个地区用于疾病,预防,和治疗。大约200年前,大多数医学治疗都是基于草药。尤其是在西方,由于对抗疗法的兴起,草药治疗的使用在1960年代开始减弱。近年来,然而,由于多种原因,人们对草药的兴趣和需求重新抬头,包括关于其功效的声明,将消费者的偏好转向天然药物,现代药物的高成本和负面副作用,科学研究和技术创新带来的草药进步。对药用植物及其典型用途的探索可能会导致产生减少不良反应的先进药物。这篇综述旨在概述纳米载体在植物治疗中的应用,包括它的现状,最近的进步,挑战,和未来的前景。目的是使研究人员全面了解历史背景,当前状态,以及这一新兴领域的潜在未来发展。鉴于此,已经讨论了基于纳米载体的自然伤口愈合治疗的优势,专注于纳米纤维,纳米粒子,纳米乳液,和纳米凝胶。
    The treatment of wounds is a serious problem all over the world and imposes a huge financial burden on each and every nation. For a long time, researchers have explored wound dressing that speeds up wound healing. Traditional wound dressing does not respond effectively to the wound-healing process as expected. Therapeutic active derived from plant extracts and extracted bioactive components have been employed in various regions of the globe since ancient times for the purpose of illness, prevention, and therapy. About 200 years ago, most medical treatments were based on herbal remedies. Especially in the West, the usage of herbal treatments began to wane in the 1960s as a result of the rise of allopathic medicine. In recent years, however, there has been a resurgence of interest in and demand for herbal medicines for a number of reasons, including claims about their efficacy, shifting consumer preferences toward natural medicines, high costs and negative side effects of modern medicines, and advancements in herbal medicines brought about by scientific research and technological innovation. The exploration of medicinal plants and their typical uses could potentially result in advanced pharmaceuticals that exhibit reduced adverse effects. This review aims to present an overview of the utilization of nanocarriers in plant-based therapeutics, including its current status, recent advancements, challenges, and future prospects. The objective is to equip researchers with a comprehensive understanding of the historical background, current state, and potential future developments in this emerging field. In light of this, the advantages of nanocarriers based delivery of natural wound healing treatments have been discussed, with a focus on nanofibers, nanoparticles, nano-emulsion, and nanogels.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    这项研究的重点是通过纳米沉淀过程制备用于递送环丙沙星的纳米载体。这样做是为了检查药物在胃的pH下的释放,以发现环丙沙星负载的纳米颗粒(NPs)的抗菌作用。制备的NP通过傅里叶变换红外(FTIR)光谱表征,扫描电子显微镜(SEM),和粒度分析仪(PSA)技术。药物产量,加载,并研究了缓释随时间(最多8小时)的变化。还测定了负载环丙沙星的NP对不同革兰氏阳性和革兰氏阴性细菌的抗菌活性。结果表明,纳米沉淀是将环丙沙星包封在聚(乳酸-共-乙醇酸)PLGANP中的合适方法。发现药物产量和载药量为60%。通过PSA观察到的NP的尺寸范围在5.03-6.60nm的范围内。可以得出结论,环丙沙星负载的PLGANP的纳米制剂可以在胃中使用更长的时间,以提高药物的生物利用度。
    This study focusses on the fabrication of nano-carriers for delivery of ciprofloxacin through the nanoprecipitation process. This was done to examine the release of drug at the pH of stomach to find out the antibacterial action of ciprofloxacin loaded nanoparticles (NPs). Prepared NPs were characterized by Fourier Transform Infra-Red (FTIR) spectroscopy, Scanning Electron Microscopy (SEM), and particle size analyzer (PSA) techniques. Drug yield, loading, and sustained release was studied as function of time (up to 8 h). Antibacterial activity of ciprofloxacin loaded NPs were also determined against different gram-positive and gram-negative bacteria. Results revealed that nanoprecipitation is a suitable method for encapsulation of ciprofloxacin in poly(lactic-co-glycolic acid) PLGA NPs. The drug yield and drug loading were found to be 60%. The size range of NPs observed by PSA was in the range of 5.03-6.60 nm. It can be concluded that nanoformulation of ciprofloxacin loaded PLGA NPs can be used in stomach for longer period of time to enhance the bioavailability of the drug.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号